Is TALS or JNJ a better dividend investment in 2026?

TALS currently yields 55.51% with a 5% 5-year dividend growth rate. JNJ yields 3.36% with 5.8% growth. The better choice depends on your goal: TALS offers higher current income.

What is the dividend yield difference between TALS and JNJ?

TALS has a forward dividend yield of 55.51% ($1.51/share annually). JNJ yields 3.36% ($4.96/share annually). The yield gap is 52.15 percentage points.

Home › Compare › TALS vs JNJ

TALS vs JNJ: Dividend Comparison 2026

TALS yields 55.51% · JNJ yields 3.36%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 TALS wins by $501.6K in total portfolio value

INVESTMENT

TIME HORIZON10 years

TALS

● Live price

55.51%

Share price

$2.72

Annual div

$1.51

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$521.6K

Annual income

$114,803.66

Full TALS calculator →

JNJ

Johnson & Johnson

● Live price

3.36%

Share price

$147.50

Annual div

$4.96

5Y div CAGR

5.8%

Payout ratio

55%

After 10 yrs · $10,000 · DRIP

Portfolio value

$20.0K

Annual income

$827.78

Full JNJ calculator →

Portfolio growth — TALS vs JNJ

📍 TALS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	TALS	JNJ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, TALS + JNJ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

TALS pays

JNJ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TALS

Annual income on $10K today (after 15% tax)

$4,718.75/yr

After 10yr DRIP, annual income (after tax)

$97,583.11/yr

JNJ

Annual income on $10K today (after 15% tax)

$285.83/yr

After 10yr DRIP, annual income (after tax)

$703.61/yr

At 15% tax rate, TALS beats the other by $96,879.50/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TALS + JNJ for your $10,000?

TALS: 50%JNJ: 50%

100% JNJ50/50100% TALS

Portfolio after 10yr

$270.8K

Annual income

$57,815.72/yr

Blended yield

21.35%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

TALS

Analyst Ratings

Buy

Hold

Consensus: Hold

Altman Z

5.6

Piotroski

1/9

JNJ

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$228.73

+55.1% upside vs current

Range: $190.00 — $265.00

Altman Z

5.2

Piotroski

4/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TALS buys

JNJ buys

No recent congressional trades found for TALS or JNJ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricTALSJNJ

Forward yield	55.51% ✓	3.36%
Annual dividend / share	$1.51	$4.96 ✓
Payout ratio	50% ✓	55%
1-year div growth	0%	4.2% ✓
5-year div CAGR	0%	5.8% ✓
Portfolio after 10y	$521.6K ✓	$20.0K
Annual income after 10y	$114,803.66 ✓	$827.78
Total dividends collected	$425.9K ✓	$5.6K
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare
Analyst consensus	Hold	Buy

Year-by-year: TALS vs JNJ ($10,000, DRIP)

Year	TALS Portfolio	TALS Income/yr	JNJ Portfolio	JNJ Income/yr	Gap
1← crossover	$16,251	$5,551.47	$10,676	$355.77	+$5.6K → TALS
2	$25,821	$8,431.73	$11,407	$389.39	+$14.4K → TALS
3	$40,148	$12,520.17	$12,198	$426.53	+$27.9K → TALS
4	$61,153	$18,193.88	$13,056	$467.62	+$48.1K → TALS
5	$91,333	$25,899.34	$13,987	$513.12	+$77.3K → TALS
6	$133,877	$36,150.61	$14,998	$563.56	+$118.9K → TALS
7	$192,771	$49,523.37	$16,098	$619.52	+$176.7K → TALS
8	$272,910	$66,644.47	$17,295	$681.69	+$255.6K → TALS
9	$380,191	$88,177.34	$18,599	$750.82	+$361.6K → TALS
10	$521,608	$114,803.66	$20,022	$827.78	+$501.6K → TALS

TALS vs JNJ: Complete Analysis 2026

TALS — Stock

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

Full TALS Calculator →

JNJ — Healthcare

Johnson & Johnson is a Dividend King with 62+ years of consecutive dividend increases. A healthcare conglomerate spanning pharmaceuticals, MedTech, and consumer health. JNJ spun off its consumer segment as Kenvue in 2023, focusing on higher-margin pharma and medical devices.

Full JNJ Calculator →

📬

Get this TALS vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TALS vs SCHD TALS vs JEPI TALS vs O TALS vs KO TALS vs MAIN TALS vs ABBV TALS vs MRK TALS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.